Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2019: Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer

Researchers from The University of Texas MD Anderson Cancer Center have identified a standardised protocol that uses image-guided breast biopsies to reliably predict residual disease in breast cancer patients and that potentially identifies exceptional responders who may not require surgery.

UtiliSing this technique, a multi-centre clinical trial led by Henry Kuerer, M.D., Ph.D., professor of Breast Surgical Oncology, is studying the elimination of surgery in exceptional responders after neoadjuvant chemotherapy (NAC).

Pooled analysis results of this technique derived from patient data at the Royal Marsden Hospital, Seoul National University Hospital and MD Anderson were presented at the 2019 San Antonio Breast Cancer Symposium.

Data analysed from 166 women in the study showed that the cancer could be completely eradicated with NAC given first, also called overall pathologic complete response (pCR) in 51.2%.

This high rate of pCR suggests that many patients may not benefit from surgery if the cancer already is eradicated.

When the image-guided biopsy was representative, the false negative rate (FNR) across the whole cohort was 18.7%.

However, when using MD Anderson criteria for selection of patients to study the safety of eliminating breast cancer surgery, the analysis of accuracy of vacuum assisted biopsies in cases with a residual imaging abnormality of < 2 centimeters to allow adequate sampling and at least six representative biopsies taken (n=76) showed an FNR of 3.2%, a negative predictive value (NPV) of 97.4% and an overall accuracy of 89.5%.

These findings suggest an optimal post-NAC biopsy protocol to support omitting surgery and the ability to accurately predict residual cancer.

“For many breast cancer patients who need chemotherapy to increase survival, giving it first can completely kill the cancer. This finding motivated us to find an accurate way to identify these patients to study the safety of eliminating surgery in our ongoing clinical trial. The key finding from this multi-centre trial illustrates that we must be super selective regarding the specific patient population to study this new paradigm,” said Kuerer. “This research suggests a standardised protocol may be able to eventually eliminate surgery in a select group of patients, while also closely and accurately monitoring their cancer for recurrence.”

The majority (n=160) of patients in the analysis had invasive ductal carcinoma (IDC) with phenotype distribution of 18.7% (n=31) hormone receptor (HR) positive/human epidermal growth factor receptor (HER) 2 negative, 28.3% (n=47) HR and HER2 positive, 17.5% (n=29) HR negative/HER2 positive and 35.5% (n=59) triple negative (TN) breast cancer.

A subgroup analysis in patients with HER2 positive or TN cancer (n=66) who are most likely to be exceptional responders and achieve pCR showed similar accuracy of the technique with an FNR of 4.2%, an NPV of 97.2% and an overall accuracy of 87.9%.

Median tumour size on pre-treatment imaging was 33.5 mm (range: 12 – 100) and median number of samples was 6 (range: 2 – 18).

The biopsy was performed under ultrasound (n=129) or stereo guidance (n=37) and in 159 cases was representative of the tumour bed.

“This data shows that through image-guided vacuum assisted biopsies on patients who achieve a complete pathologic response to chemotherapy, accurate predictions of residual disease can be made, opening the door for potential avoidance of surgery,” said Kuerer. “This would be a major step toward improving quality of life for patients with breast cancer.”

Future additional studies will be designed to deescalate treatment in NAC-exceptional responders and study the safety of eliminating surgery for this select patient population.

Source: MD Anderson Cancer Center

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation